Bafna Pharmaceuticals Limited has informed the Exchange regarding the outcome Board meeting held on August 12, 2025
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals' Board met on August 12, 2025 and approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations rose to about INR 3,462 lakhs from INR 3,329 lakhs in the same quarter last year, a roughly 4% increase. The company swung to a profit of INR 339 lakhs compared with a loss of INR 72 lakhs in Q1 FY25, with basic EPS of INR 1.43 versus a negative INR 0.31 a year ago. The Board also set September 19, 2025 as the date for the 30th Annual General Meeting (to be held via video conferencing), with book closure from September 13 to 19, 2025. Additionally, the Nomination & Remuneration Committee was reconstituted with a new Chairman and members.
The strong swing back to profitability and modest revenue growth in Q1 are positive signals for shareholders, though the auditor highlighted overdue foreign receivables (INR 123 lakhs), a disputed income tax refund (INR 45 lakhs) and past SEBI penalties related to minimum public shareholding as items still under resolution. The completed sale of Madhavaram unit assets and the promoter offer-for-sale restoring public shareholding are corporate housekeeping steps that should reduce overhang on the stock.